Branko Miladinovic

Featured in: Favicon

Articles

Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer

May 17, 2024 | europeanurology.com | Sabine D. Brookman-May |Janssen Research |Stephen J. Freedland |Spring House |Marc E. Buyse |Branko Miladinovic | +5 more

To read this article in full you will need to make a paymentSubscribe to European UrologyReferencesMetastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 35: 3097-3104ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. Ann Oncol.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.